Blogs

In the world of autoimmune diagnostics, time and accuracy are everything. Traditional serological testing often involves multiple assays, manual steps, and long turnaround times. AliveDx is changing that with the MosaiQ® AiPlex CTDplus, a fully automated multiplex microarray immunoassay designed

In-vitro diagnostics (IVD) is entering a new era, one where artificial intelligence (AI) and multiplexed immunoassays converge to deliver fast, smart and accurate results. At AliveDx, we’re proud to be at the forefront of this transformation with our MosaiQ® and

In–vitro diagnostics (IVD) is undergoing a transformation, driven by automation and a syndromic approach enabled by multiplexing technologies. At AliveDx, we’re proud to lead this evolution with the MosaiQ AiPlex® VAS microarray, a fully automated multiplex immunoassay designed to detect

Autoimmune connective tissue diseases1 (CTD) such as lupus, Sjögren’s syndrome, and systemic sclerosis present a diagnostic challenge due to overlapping symptoms and complex antibody profiles. At AliveDx, we’re committed to the challenge of simplifying that complexity through innovative in-vitro diagnostic